Human herpes simplex virus: Life cycle and development of inhibitors

  title={Human herpes simplex virus: Life cycle and development of inhibitors},
  author={Marina K Kukhanova and Anna N Korovina and Sergey N. Kochetkov},
  journal={Biochemistry (Moscow)},
WHO reports that 90% of human population is infected by different types of herpesviruses, which develop latency or cause oral and genital herpes, conjunctivitis, eczema herpeticum, and other diseases. Herpesvirus almost always accompanies HIV-infection and complicates AIDS treatment. Herpes simplex virus type 1 is one of the most wide spread viruses from the Herpesviridae family. HSV virion, genome structure, replication mechanisms, antiherpes drug development strategies, including design of… 

Herpesvirus Polymerase Inhibitors

Experimental Dissection of the Lytic Replication Cycles of Herpes Simplex Viruses in vitro

The lytic replication cycles of herpes simplex viruses are reviewed and dissected, discussing key steps involved in cell infection and the processes that yield new virions to facilitate the identification of the mechanisms of action of anti-HSV compounds.

Current and Emerging Therapies for Ocular Herpes Simplex Virus Type-1 Infections

The lifecycle of HSV-1 as it pertains to corneal infections and the clinically approved as well as emerging treatments to combat HSV1 infections are discussed and some newly identified host targets for the antiviral drug development are highlighted.

Herpesvirus: an underestimated virus

This short review proposes to present concisely the history of HSV, its taxonomy, physical structure, and replication and to explore the pathogenesis of the infection, clinical manifestations, laboratory diagnosis, treatment, prophylaxis and epidemiology of the diseases.

Herpes Simplex Virus: Methods and Protocols

This book provides protocols currently in use in leading laboratories in many fields of HSV-1 research, covering basic aspects of virus structure, the prevalence of and diseases caused by the virus, replication in cultured cells, viral latency, antiviral defenses, and the mechanisms that the virus uses to counteract these defenses.

Herpes Simplex Virus Establishment, Maintenance, and Reactivation: In Vitro Modeling of Latency

Cell culture models that recapitulate latent infection provide valuable insight on the host processes regulating viral establishment and maintenance of latency in herpes simplex viruses.

Tour de Herpes: Cycling Through the Life and Biology of HSV-1.

This book provides protocols currently in use in leading laboratories in many fields of HSV-1 research, covering basic aspects of virus structure, the prevalence of and diseases caused by the virus, replication in cultured cells, viral latency, antiviral defenses, and the mechanisms that the virus uses to counteract these defenses.

Ginkgolic Acid Inhibits Herpes Simplex Virus Type 1 Skin Infection and Prevents Zosteriform Spread in Mice

Ginkgolic acid’s antiviral activity against HSV-1 skin infection in BALB/cJ mice is reported and it is anticipated it to be effective against additional cutaneous and potentially systemic viral infections.

Harringtonine Inhibits Herpes Simplex Virus Type 1 Infection by Reducing Herpes Virus Entry Mediator Expression

Harringtonine showed antiviral activity against HSV-1 and ACV-resistant strains by targeting HVEM and could be a promising therapeutic candidate for mitigating HSv-1-induced-pathogenesis.

Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection

Currently available anti-herpetic therapies, novel molecules being assessed in clinical trials and new botanical compounds reported in the last 20 years with antiviral activities against HSVs that might represent future treatments against these viruses are reviewed.



Crystal Structure of the Herpes Simplex Virus 1 DNA Polymerase*

The first crystal structure of a herpesvirus polymerase is presented, the Herpes Simplex Virus type 1 DNA polymerase, at 2.7 Å resolution and a novel inhibition mechanism is proposed in which a representative of a series of non-nucleosidic viral polymerase inhibitors, the 4-oxo-dihydroquinolines, binds at the polymerase active site interacting non-covalently with both the polymer enzyme and the DNA duplex.

Herpesviruses: latency and reactivation – viral strategies and host response

  • B. Grinde
  • Medicine, Biology
    Journal of oral microbiology
  • 2013
The review starts by introducing possible viral strategies in general and the particular biology and host relationship of the various human herpesviruses, including their pathology, are examined subsequently.

New helicase-primase inhibitors as drug candidates for the treatment of herpes simplex disease

New inhibitors of the HSV helicase-primase with potent in vitro anti-herpes activity, a novel mechanism of action, a low resistance rate and superior efficacy against HSV in animal models are reported.

Antiviral agents for herpes simplex virus.

Famciclovir and Valaciclovir Differ in the Prevention of Herpes Simplex Virus Type 1 Latency in Mice: a Quantitative Study

Significantly less latent virus was detected by all four methods, however, in Ganglia obtained from mice that had been treated with FCV in comparison with the amount detected in ganglia from mice That had been treating with VACV, but in no case was latency completely eliminated.

Inhibition of Herpes Simplex Virus by Polyamines

Dextran-propan-1,3-diamine (DPD) was found to be the most potent of all the compounds examined and could have an advantage as a topical application in combination therapy of HSV lesions.

Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy.

The heterogeneity within the viral populations and the temporal changes of drug-resistant viruses found in this HSCT recipient were remarkable, showing a rapid evolution of HSV-1.

Herpes simplex virus helicase-primase inhibitors are active in animal models of human disease

These studies validate the use of helicase-primase inhibitors for the treatment of acute herpesvirus infections and provide new lead compounds for optimization and design of superior anti-HSV agents.

Mutations in the DNA polymerase and thymidine kinase genes of herpes simplex virus clinical isolates resistant to antiherpetic drugs

The phylogenetic sequence analysis showed that the ul30 and ul23 sequences of clinical isolates were close to those of L2, and that ul30 conserved regions differed between HSV-1 isolates and L2 only in point mutations and degenerated substitutions.